LONDON, March 16, 2017 /PRNewswire/ -- "Global Rheumatoid Arthritis Drug Market Outlook 2022" report gives comprehensive clinical and non-clinical insight on various trends associated with the rheumatoid arthritis drug market across the developed and developing market. Report helps to identify the basic classification and molecular mechanism of action of rheumatoid arthritis drugs available in the market. The top 5 leading DMARDs (Humira, Enbrel, Remicade, Simponi & Otezla) have dominated the overall anti-rheumatics market with total revenue surpassing more than US$ 25 Billion in 2016. These drugs will remain strong over the next 5 years, despite expected biosimilar competition.
Therapeutic advances have transformed the rheumatoid arthritis treatment paradigm over the last 20 years, from focusing on symptom management to now aiming for slowed disease progression and even disease remission. Disease-modifying biological medicines have ushered in a new age of treatment by targeting the cells involved in the progression of the disease.
These medicines have dramatically slowed or even reversed the negative physical effects associated with the disease and made clinical remission possible for patients with severe rheumatoid arthritis. The market of anti-rheumatics is growing at a constant speed globally. There are some driving factors which are accelerating the growth of anti-rheumatics market such as the increasing number of patients with rheumatoid arthritis, rise in research and development activities, increasing awareness among people about rheumatoid arthritis, and improved healthcare infrastructure in the region.
Until late in the 20th century, the therapy of rheumatic diseases relied on the use of drugs that had been developed through empirical approaches without detailed understanding of the molecular mechanisms involved. That approach changed with the introduction of biologic therapeutics at the end of the 20th century and by the recent development of small-molecule inhibitors of intracellular signal transduction pathways.
TNF-blocking biologic agents were introduced into the therapy of rheumatoid arthritis and other autoimmune and inflammatory diseases in the late 1990s. Further biologic agents targeting cytokine networks or specific lymphocyte subsets have since been added to the armamentarium of anti-rheumatic therapy. During the last few years, another wave of novel discoveries led to the development of a new class of small molecule anti-inflammatory compounds targeting intracellular signal transduction molecules, such as tyrosine kinases.
The most valuable development in treating Rheumatoid Arthritis will be biomarkers to help diagnose it early, identify those with more severe disease requiring more aggressive treatment, and indicate the most appropriate therapy for each person. Biomarkers may even help to decide the best time to step down therapy when a patient is in remission. There is a huge amount of research taking place, which reflects the excellent relationships between rheumatology health care professionals and people with Rheumatoid Arthritis.
"Global Rheumatoid Arthritis Drug Market Outlook 2022" report highlights:
- Classification & Molecular Mechanism of Rheumatoid Arthritis Drugs
- Synthetic DMARDs as Rheumatoid Arthritis Drug
- Biological Agents as Rheumatoid Arthritis Drug
- Global Market of Rheumatoid Arthritis Drug
- Global Tendencies in Use of Antirheumatics
- Global Rheumatoid Arthritis Drug Market Future Prospect
Download the full report: https://www.reportbuyer.com/product/4753869/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Research Advisor at Reportbuyer.com
Tel: +44 208 816 85 48